TAS-102

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
TAS-102
Accession Number
DB08937
Type
Small Molecule
Groups
Investigational
Description

TAS-102 (Taiho Pharma USA, Inc.) is an anti-cancer drug under development and in stage 3 clinical trials for the treatment of colorectal cancer. It is composed of the thymidine phosphorylase inhibitor (TPI) tipiracil and the cytotoxin trifluridine. Trifluridine inhibits tumor growth by being incorporated into DNA during DNA synthesis. Tipiracil prevents trifluridine from being broken down when taken orally.

Synonyms
Not Available
Categories
UNII
Not Available
CAS number
733030-01-8
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
  1. Emura T, Suzuki N, Yamaguchi M, Ohshimo H, Fukushima M: A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Int J Oncol. 2004 Sep;25(3):571-8. [PubMed:15289858]
  2. Link [Link]
External Links
PubChem Substance
347910389
Wikipedia
TAS-102

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentAdvanced Solid Tumors1
1CompletedTreatmentAdvanced Gastrointestinal Tumors1
1CompletedTreatmentAdvanced Solid Tumors3
1CompletedTreatmentAdvanced Solid Tumors (Excluding Breast Cancer)2
1CompletedTreatmentAdvanced or Metastatic Solid Tumors1
1Not Yet RecruitingTreatmentRectal Adenocarcinoma / Stage IIA Rectal Cancer AJCC v8 / Stage IIB Rectal Cancer AJCC v8 / Stage III Rectal Cancer AJCC v8 / Stage IIIA Rectal Cancer AJCC v8 / Stage IIIB Rectal Cancer AJCC v8 / Stage IIIC Rectal Cancer AJCC v81
1RecruitingTreatmentColorectal Cancers1
1RecruitingTreatmentGastric Adenocarcinoma / Gastrooesophageal Cancer1
1RecruitingTreatmentHepatic Metastases / Malignant Neoplasm of Colon / Rectal Carcinoma1
1RecruitingTreatmentMalignancies / Neoplasms / Neuroendocrine Tumors / Tumors1
1RecruitingTreatmentMetastatic Colon Carcinoma / Metastatic Colorectal Carcinoma / Metastatic Rectal Carcinoma / RAS Family Gene Mutation / Stage III Colon Cancer AJCC v7 / Stage III Colorectal Cancer AJCC v7 / Stage III Rectal Cancer AJCC v7 / Stage IIIA Colon Cancer AJCC v7 / Stage IIIA Colorectal Cancer AJCC v7 / Stage IIIA Rectal Cancer AJCC v7 / Stage IIIB Colon Cancer AJCC v7 / Stage IIIB Colorectal Cancer AJCC v7 / Stage IIIB Rectal Cancer AJCC v7 / Stage IIIC Colon Cancer AJCC v7 / Stage IIIC Colorectal Cancer AJCC v7 / Stage IIIC Rectal Cancer AJCC v7 / Stage IV Colon Cancer AJCC v7 / Stage IV Colorectal Cancer AJCC v7 / Stage IV Rectal Cancer AJCC v7 / Stage IVA Colon Cancer AJCC v7 / Stage IVA Colorectal Cancer AJCC v7 / Stage IVA Rectal Cancer AJCC v7 / Stage IVB Colon Cancer AJCC v7 / Stage IVB Colorectal Cancer AJCC v7 / Stage IVB Rectal Cancer AJCC v71
1RecruitingTreatmentRectal Adenocarcinoma / Recurrent Rectal Carcinoma / Stage IV Rectal Cancer AJCC v7 / Stage IVA Rectal Cancer AJCC v7 / Stage IVB Rectal Cancer AJCC v71
1RecruitingTreatmentRefractory Solid Tumors1
1, 2CompletedTreatmentColorectal Cancers1
1, 2RecruitingTreatmentAdvanced Gastric Cancer / Colorectal Adenocarcinoma / Gastric Adenocarcinoma / Non-Resectable Cholangiocarcinoma / Pancreatic Adenocarcinoma Metastatic / Stage III Colorectal Cancer / Stage III Gastric Cancer / Stage III Pancreatic Cancer / Stage IV Colorectal Cancer / Stage IV Pancreatic Cancer / Stage IVA Colorectal Cancer / Stage IVB Colorectal Cancer / Unresectable Digestive System Adenocarcinoma / Unresectable Pancreatic Carcinoma1
1, 2RecruitingTreatmentColorectal Cancers1
1, 2RecruitingTreatmentNeoplasms, Colorectal1
2Active Not RecruitingTreatmentCholangiocarcinomas / Stage III Gallbladder Cancer AJCC V7 / Stage IIIA Gallbladder Cancer AJCC v7 / Stage IIIB Gallbladder Cancer AJCC v7 / Stage IV Gallbladder Cancer AJCC v7 / Stage IVA Gallbladder Cancer AJCC v7 / Stage IVB Gallbladder Cancer AJCC v71
2Active Not RecruitingTreatmentPreviously Treated Metastatic Colorectal Cancer1
2Active Not RecruitingTreatmentSquamous Cell Lung Carcinoma1
2CompletedTreatmentRefractory, metastatic Colorectal cancer1
2Not Yet RecruitingTreatmentBRAF V600 Wild Type / KRAS Gene Mutation Negative / Metastatic Colon Adenocarcinoma / Metastatic Colorectal Carcinoma / Metastatic Rectal Adenocarcinoma / NRAS Gene Mutation Negative / Progressive Disease / RAS Wild Type / Stage IV Colon Cancer AJCC v8 / Stage IV Colorectal Cancer AJCC v8 / Stage IV Rectal Cancer AJCC v8 / Stage IVA Colon Cancer AJCC v8 / Stage IVA Colorectal Cancer AJCC v8 / Stage IVA Rectal Cancer AJCC v8 / Stage IVB Colon Cancer AJCC v8 / Stage IVB Colorectal Cancer AJCC v8 / Stage IVB Rectal Cancer AJCC v8 / Stage IVC Colon Cancer AJCC v8 / Stage IVC Colorectal Cancer AJCC v8 / Stage IVC Rectal Cancer AJCC v81
2Not Yet RecruitingTreatmentHigh-grade Extra Pulmonary Neuroendocrine Cancer1
2Not Yet RecruitingTreatmentMetastatic Triple Negative Breast Cancer1
2RecruitingTreatmentAdvanced Bile Duct Carcinoma / Advanced Gallbladder Carcinoma / Refractory Bile Duct Carcinoma / Refractory Gallbladder Carcinoma / Stage III Distal Bile Duct Cancer AJCC v8 / Stage III Gallbladder Cancer AJCC v8 / Stage III Intrahepatic Bile Duct Cancer AJCC v8 / Stage IIIA Distal Bile Duct Cancer AJCC v8 / Stage IIIA Gallbladder Cancer AJCC v8 / Stage IIIA Intrahepatic Bile Duct Cancer AJCC v8 / Stage IIIB Distal Bile Duct Cancer AJCC v8 / Stage IIIB Gallbladder Cancer AJCC v8 / Stage IIIB Intrahepatic Bile Duct Cancer AJCC v8 / Stage IV Distal Bile Duct Cancer AJCC v8 / Stage IV Gallbladder Cancer AJCC v8 / Stage IV Intrahepatic Bile Duct Cancer AJCC v8 / Stage IVA Gallbladder Cancer AJCC v8 / Stage IVB Gallbladder Cancer AJCC v81
2RecruitingTreatmentAdvanced Colorectal Carcinoma / Metastatic Colon Adenocarcinoma / Metastatic Rectal Adenocarcinoma / Recurrent Colon Adenocarcinoma / Recurrent Colorectal Adenocarcinoma / Recurrent Rectal Adenocarcinoma / Stage III Colon Cancer AJCC v8 / Stage III Colorectal Cancer AJCC v8 / Stage III Rectal Cancer AJCC v8 / Stage IIIA Colon Cancer AJCC v8 / Stage IIIA Colorectal Cancer AJCC v8 / Stage IIIB Colorectal Cancer AJCC v8 / Stage IIIB Rectal Cancer AJCC v8 / Stage IIIC Colon Cancer AJCC v8 / Stage IIIC Colorectal Cancer AJCC v8 / Stage IV Colon Cancer AJCC v8 / Stage IVA Colorectal Cancer AJCC v8 / Stage IVA Rectal Cancer AJCC v8 / Stage IVB Colon Cancer AJCC v8 / Stage IVB Colorectal Cancer AJCC v8 / Stage IVB Rectal Cancer AJCC v8 / Stage IVC Colon Cancer AJCC v8 / Stage IVC Colorectal Cancer AJCC v8 / Stage IVC Rectal Cancer AJCC v8 / Unresectable Colon Adenocarcinoma / Unresectable Colorectal Carcinoma / Unresectable Rectal Adenocarcinoma1
2RecruitingTreatmentBladder Cancers1
2RecruitingTreatmentKRAS Gene Mutation / Metastatic Colorectal Carcinoma / NRAS Gene Mutation / Stage III Colorectal Cancer AJCC v8 / Stage IIIA Colorectal Neuroendocrine Tumor AJCC v8 / Stage IIIB Colorectal Cancer AJCC v8 / Stage IIIC Colorectal Cancer AJCC v8 / Stage IV Colorectal Cancer AJCC v8 / Stage IVA Colorectal Cancer AJCC v8 / Stage IVB Colorectal Cancer AJCC v8 / Stage IVC Colorectal Cancer AJCC v8 / Unresectable Carcinoma1
2RecruitingTreatmentRefractory Colorectal Carcinoma / Stage III Colorectal Cancer AJCC v8 / Stage IIIA Colorectal Cancer AJCC v8 / Stage IIIB Colorectal Cancer AJCC v8 / Stage IIIC Colorectal Cancer AJCC v8 / Stage IV Colorectal Cancer AJCC v8 / Stage IVA Colorectal Cancer AJCC v8 / Stage IVB Colorectal Cancer AJCC v8 / Stage IVC Colorectal Cancer AJCC v81
2SuspendedTreatmentMalignant Neoplasm of Pancreas1
2TerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2TerminatedTreatmentMetastatic Colorectal Cancer (MCRC)1
2, 3CompletedTreatmentMetastatic Colorectal Cancer (MCRC)1
2, 3RecruitingTreatmentColorectal Cancers / Metastasis1
3CompletedTreatmentColorectal Cancers2
3CompletedTreatmentRefractory Metastatic Gastric Cancer1
3WithdrawnTreatmentCarcinoma NOS / Metastatic Colorectal Cancer (MCRC)1
Not AvailableApproved for MarketingNot AvailableMetastatic Colorectal Cancer (MCRC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on March 07, 2014 10:52 / Updated on December 02, 2019 08:33